• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Characterization of cardiac angiotensin converting enzyme (ACE) and in vivo inhibition following oral quinapril to rats.大鼠口服喹那普利后心脏血管紧张素转换酶(ACE)的特性及体内抑制作用
Br J Pharmacol. 1990 Jul;100(3):651-5. doi: 10.1111/j.1476-5381.1990.tb15862.x.
2
Angiotensin converting enzyme in the rat heart: studies of its inhibition in vitro and ex vivo.大鼠心脏中的血管紧张素转换酶:其体外和体内抑制作用的研究。
Clin Exp Pharmacol Physiol. 1989 Apr;16(4):309-13. doi: 10.1111/j.1440-1681.1989.tb01563.x.
3
Comparative studies of tissue inhibition by angiotensin converting enzyme inhibitors.血管紧张素转换酶抑制剂对组织抑制作用的比较研究。
J Hypertens Suppl. 1989 Sep;7(5):S11-6.
4
Inhibition of angiotensin-converting enzyme (ACE) in plasma and tissue.
J Cardiovasc Pharmacol. 1990;15 Suppl 2:S6-13. doi: 10.1097/00005344-199000152-00003.
5
Two binding sites on angiotensin-converting enzyme: evidence from radioligand binding studies.血管紧张素转换酶上的两个结合位点:放射性配体结合研究的证据。
Mol Pharmacol. 1992 Aug;42(2):286-93.
6
Localization of angiotensin converting enzyme in rat heart.血管紧张素转换酶在大鼠心脏中的定位
Circ Res. 1991 Jan;68(1):141-9. doi: 10.1161/01.res.68.1.141.
7
Relative inhibitory potency and plasma drug levels of angiotensin converting enzyme inhibitors in the rat.大鼠体内血管紧张素转换酶抑制剂的相对抑制效力及血浆药物水平
Clin Exp Pharmacol Physiol. 1988 Feb;15(2):123-9. doi: 10.1111/j.1440-1681.1988.tb01053.x.
8
Moexipril and quinapril inhibition of tissue angiotensin-converting enzyme activity in the rat: evidence for direct effects in heart, lung and kidney and stimulation of prostacyclin generation.莫昔普利和喹那普利对大鼠组织血管紧张素转换酶活性的抑制作用:对心脏、肺和肾脏的直接作用及刺激前列环素生成的证据
J Endocrinol Invest. 2003 Jan;26(1):79-83. doi: 10.1007/BF03345127.
9
Structural constraints of inhibitors for binding at two active sites on somatic angiotensin converting enzyme.抑制剂与体细胞血管紧张素转换酶两个活性位点结合的结构限制因素。
Eur J Pharmacol. 1994 Feb 15;266(3):201-11. doi: 10.1016/0922-4106(94)90128-7.
10
Acute and long-term dose-response study of quinapril on hormonal profile and tissue angiotensin-converting enzyme in Wistar rats.
J Cardiovasc Pharmacol. 1996 Jul;28(1):11-8. doi: 10.1097/00005344-199607000-00003.

引用本文的文献

1
Liver Protective Effects of Renin-Angiotensin System Inhibition Have No Survival Benefits in Hepatocellular Carcinoma Induced By Repetitive Administration of Diethylnitrosamine in Mice.肾素-血管紧张素系统抑制的肝脏保护作用对二乙基亚硝胺重复给药诱导的小鼠肝细胞癌无生存益处。
Open Access Maced J Med Sci. 2018 Jun 6;6(6):955-960. doi: 10.3889/oamjms.2018.167. eCollection 2018 Jun 20.
2
ACE phenotyping in human heart.人类心脏中的ACE表型分析
PLoS One. 2017 Aug 3;12(8):e0181976. doi: 10.1371/journal.pone.0181976. eCollection 2017.
3
The evolution of renin-angiotensin blockade: angiotensin-converting enzyme inhibitors as the starting point.肾素-血管紧张素阻断的演变:血管紧张素转换酶抑制剂作为起点。
Curr Hypertens Rep. 2010 Apr;12(2):67-73. doi: 10.1007/s11906-010-0091-9.
4
Do ACE inhibitors all provide the same outcomes benefits in high-risk cardiovascular patients?在高危心血管疾病患者中,所有的血管紧张素转换酶抑制剂都能带来相同的疗效益处吗?
Curr Hypertens Rep. 2008 Aug;10(4):286-92. doi: 10.1007/s11906-008-0053-7.
5
Fosinopril. Clinical pharmacokinetics and clinical potential.福辛普利。临床药代动力学与临床应用潜力。
Clin Pharmacokinet. 1997 Jun;32(6):460-80. doi: 10.2165/00003088-199732060-00003.
6
The QUinapril Ischemic Event Trial (QUIET) design and methods: evaluation of chronic ACE inhibitor therapy after coronary artery intervention.
Cardiovasc Drugs Ther. 1993 Apr;7(2):273-82. doi: 10.1007/BF00878518.
7
Fosinopril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in essential hypertension.福辛普利。对其药效学和药代动力学特性以及在原发性高血压治疗中的潜力的综述。
Drugs. 1992 Jan;43(1):123-40. doi: 10.2165/00003495-199243010-00009.

本文引用的文献

1
Protein measurement with the Folin phenol reagent.使用福林酚试剂进行蛋白质测定。
J Biol Chem. 1951 Nov;193(1):265-75.
2
Preparation of iodine-131 labelled human growth hormone of high specific activity.高比活度碘-131标记人生长激素的制备
Nature. 1962 May 5;194:495-6. doi: 10.1038/194495a0.
3
Long-term control of congestive heart failure with captopril.
Am J Cardiol. 1982 Apr 21;49(6):1489-96. doi: 10.1016/0002-9149(82)90366-6.
4
Molecular and catalytic properties of rabbit testicular dipeptidyl carboxypeptidase.兔睾丸二肽基羧肽酶的分子与催化特性
J Biol Chem. 1982 Dec 10;257(23):14128-33.
5
Effect of converting enzyme inhibitor (SQ14,225) on myocardial hypertrophy in spontaneously hypertensive rats.
Hypertension. 1980 Mar-Apr;2(2):169-76. doi: 10.1161/01.hyp.2.2.169.
6
Captopril in heart failure. A double blind controlled trial.卡托普利治疗心力衰竭。一项双盲对照试验。
Br Heart J. 1984 Nov;52(5):530-5. doi: 10.1136/hrt.52.5.530.
7
Captopril reduces purine loss and reperfusion arrhythmias in the rat heart after coronary artery occlusion.卡托普利可减少大鼠冠状动脉闭塞后心脏的嘌呤损失和再灌注心律失常。
Eur J Pharmacol. 1984 Apr 13;100(1):113-7. doi: 10.1016/0014-2999(84)90323-6.
8
Interactions between coronary occlusion and the renin-angiotensin system in the dog.犬冠状动脉闭塞与肾素-血管紧张素系统之间的相互作用。
Basic Res Cardiol. 1983 Sep-Oct;78(5):518-33. doi: 10.1007/BF01906463.
9
The NH2- and COOH-terminal sequences of the angiotensin-converting enzyme isozymes from rabbit lung and testis.
Biochem Biophys Res Commun. 1982 Aug;107(3):1097-103. doi: 10.1016/0006-291x(82)90634-9.
10
Tissue-specific expression of mRNAs for dipeptidyl carboxypeptidase isoenzymes.二肽基羧肽酶同工酶mRNA的组织特异性表达。
Proc Natl Acad Sci U S A. 1982 Jul;79(14):4295-7. doi: 10.1073/pnas.79.14.4295.

大鼠口服喹那普利后心脏血管紧张素转换酶(ACE)的特性及体内抑制作用

Characterization of cardiac angiotensin converting enzyme (ACE) and in vivo inhibition following oral quinapril to rats.

作者信息

Fabris B, Yamada H, Cubela R, Jackson B, Mendelsohn F A, Johnston C I

机构信息

University of Melbourne, Department of Medicine, Austin Hospital, Heidelberg, Victoria, Australia.

出版信息

Br J Pharmacol. 1990 Jul;100(3):651-5. doi: 10.1111/j.1476-5381.1990.tb15862.x.

DOI:10.1111/j.1476-5381.1990.tb15862.x
PMID:2167741
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1917808/
Abstract
  1. Angiotensin converting enzyme (ACE) from the rat heart and lung was studied by use of the radioligand [125I]-351A. 2. Displacement of the bound radioinhibitor [125I]-351A was used to assess the relative potency of six ACE inhibitors in rat heart and lung homogenates and estimate the binding association constant (KA). 3. The KA for atrial preparations was significantly higher than that of the lung (P less than 0.025) and also the ventricles (P less than 0.005). Ventricular preparations and preparations from the lung also differed significantly (P less than 0.05). These differences in KA were noted for all six ACE inhibitors used to displace the radioligand. 4. The rank order of potency of the ACE inhibitors was quinaprilat = benazeprilat greater than perindoprilat greater than 351A greater than lisinopril greater than fosinoprilat. 5. Cardiac ACE inhibition was studied ex vivo following oral administration of quinapril to rats. Following 0.3 mg kg-1 quinapril, the time course and degree of inhibition of ventricular and atrial ACE were similar. 6. These results suggest that the detected differences in KA noted have only a limited potential biological significance. The difference in KA may reflect variations in the structure or conformation of ACE in different tissues.
摘要
  1. 利用放射性配体[125I]-351A对大鼠心脏和肺中的血管紧张素转换酶(ACE)进行了研究。

  2. 结合的放射性抑制剂[125I]-351A的置换情况被用于评估六种ACE抑制剂在大鼠心脏和肺匀浆中的相对效力,并估算结合缔合常数(KA)。

  3. 心房制剂的KA显著高于肺(P<0.025),也高于心室(P<0.005)。心室制剂和肺制剂也有显著差异(P<0.05)。用于置换放射性配体的所有六种ACE抑制剂均观察到KA的这些差异。

  4. ACE抑制剂的效力排序为喹那普利拉=贝那普利拉>培哚普利拉>351A>赖诺普利>福辛普利拉。

  5. 对大鼠口服喹那普利后,在离体条件下研究了心脏ACE抑制作用。给予0.3mg/kg喹那普利后,心室和心房ACE抑制的时间进程和程度相似。

  6. 这些结果表明,所检测到的KA差异仅具有有限的潜在生物学意义。KA的差异可能反映了不同组织中ACE结构或构象的变化。